[Comment] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?

In approximately 5% of patients with metastatic colorectal cancer, overexpression or amplification of HER2 is observed, with a higher incidence in left-sided RAS and BRAF wild-type tumours. HER2-positive metastatic colorectal cancer is one of the key molecularly distinct subgroups of colorectal cancer and might represent an oncotarget in this disease.1